In Depth 1 Feb 2023
How can cancer care be improved?
Labiotech recently asked several biotech experts the same question about tackling cancer, for a special newsletter to commemorate World Cancer Day on February 4. The 2023 theme is Close the…
ImaginAb
- Latest Posts
In Depth 1 Feb 2023
What will cancer therapy look like in 2033?
For our special newsletter on cancer, Labiotech had the opportunity to put the same question to several biotech company experts. And while no one can know for sure what the future…
News and Trends 14 Dec 2022
ImaginAb launches trial to study neoadjuvant immunotherapy
ImaginAb Inc., in collaboration with Memorial Sloan Kettering Cancer Center (MSK) and Melanoma Research Alliance (MRA), has launched an investigator-initiated phase II trial. It will explore the efficacy and safety…
News and Trends 6 Dec 2022
ImaginAb launching clinical trial for renal cancer and malignant melanoma
ImaginAb Inc., which is focused on developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and radiopharmaceutical therapy (RPT) products, is starting a phase II clinical trial. The trial, PRETZCEL, which…
ADVERTISEMENT
News and Trends 10 Nov 2022
Parthenon and ImaginAb enter into license and supply agreement for anti-cancer therapies
Precision oncology company, Parthenon Therapeutics, and ImaginAb Inc., a global biotech have entered into a multi-year, non-exclusive license and supply agreement. Under the agreement terms, Parthenon will use ImaginAb’s CD8…
News and Trends 26 Oct 2022
First patient dosed in trial to assess predictive performance of immuno-oncology therapy
The first patient has been dosed at the Macquarie University Hospital in Sydney as part of a clinical trial to evaluate whether a drug can predict patient response to immuno-oncology…
